These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19304981)

  • 21. FDA notifications. Enfuvirtide has new instructions.
    AIDS Alert; 2007 Apr; 22(4):44-5. PubMed ID: 17595723
    [No Abstract]   [Full Text] [Related]  

  • 22. Interaction between enfuvirtide, an injectable fusion inhibitor, and niacin in an HIV-infected patient.
    Oates E; Dzintars K
    Ann Pharmacother; 2010 Dec; 44(12):2014-7. PubMed ID: 21045170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Fusion inhibitor enfuvirtidE. Continuous virologic and immunologic response].
    Schäfer B
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():31. PubMed ID: 16385869
    [No Abstract]   [Full Text] [Related]  

  • 24. [Enfuvirtide: the first step for a new strategy of antiretroviral therapy].
    Bottaro EG
    Medicina (B Aires); 2007; 67(2):195-205. PubMed ID: 17593608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.
    Bienvenu B; Krivine A; Rollot F; Pietri MP; Lebault V; Meritet JF; Guerin C; Spiridon G; Salmon D; Guillevin L; Lebon P; Launay O
    J Med Virol; 2006 Oct; 78(10):1312-7. PubMed ID: 16927284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enfuvirtide (Fuzeon): the first fusion inhibitor.
    Williams IG
    Int J Clin Pract; 2003 Dec; 57(10):890-7. PubMed ID: 14712892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Enfuvirtide, mechanism of action and pharmacological properties].
    Kapić E; Becić F; Zvizdić S
    Med Arh; 2005; 59(5):313-6. PubMed ID: 16134757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short communication metabolic and mitochondrial effects of switching antiretroviral-experienced patients to enfuvirtide, tenofovir and saquinavir/ritonavir.
    Miró O; Garrabou G; López S; Deig E; Vidal I; Infante AB; Cardellach F; Casademont J; Pedrol E
    Antivir Ther; 2006; 11(5):625-30. PubMed ID: 16964831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug profile: enfuvirtide (Fuzeon, ENF, T-20).
    Pham PA
    Hopkins HIV Rep; 2003 May; 15(3):1-2. PubMed ID: 12809104
    [No Abstract]   [Full Text] [Related]  

  • 30. Enfuvirtide: first fusion inhibitor for treatment of HIV infection.
    Jamjian MC; McNicholl IR
    Am J Health Syst Pharm; 2004 Jun; 61(12):1242-7. PubMed ID: 15259753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enfuvirtide (Fuzeon).
    Proj Inf Perspect; 2003 Oct; (36):4-5. PubMed ID: 14696566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide.
    Myers SA; Selim AA; McDaniel MA; Hall R; Zhang Y; Bartlett JA; True AL
    Antivir Ther; 2006; 11(7):935-9. PubMed ID: 17302257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical perspective of fusion inhibitors for treatment of HIV.
    Rockstroh JK; Mauss S
    J Antimicrob Chemother; 2004 May; 53(5):700-2. PubMed ID: 15044424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 24 weeks in a Montreal cohort.
    Talbot A; Machouf N; Thomas R; Marcotte S; Therrien R; Lessard B; Dufresne S; Lalonde R
    J Acquir Immune Defic Syndr; 2009 Jul; 51(3):362-4. PubMed ID: 19553775
    [No Abstract]   [Full Text] [Related]  

  • 35. First-line use of enfuvirtide-containing HAART regimen with dramatic clinical and immunological improvement in three cases.
    Bourgarit A; Lascoux C; Palmer P; Tuleja E; Pintado C; Farge D; Sereni D
    AIDS; 2006 Feb; 20(3):471-3. PubMed ID: 16439888
    [No Abstract]   [Full Text] [Related]  

  • 36. [Fusion inhibitors. One year therapy with T-20--initial evaluation].
    Goebel FD
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():42-3. PubMed ID: 15373046
    [No Abstract]   [Full Text] [Related]  

  • 37. Successful long-course after failure of short-course desensitization in a patient with severe hypersensitivity reaction to enfuvirtide.
    Quiros-Roldan E; Tirelli V; Torti C; Sosta E; Tosoni C; Damiolini E; Carosi G
    AIDS; 2007 Jun; 21(10):1388-9. PubMed ID: 17545726
    [No Abstract]   [Full Text] [Related]  

  • 38. [Strategies for combating resistances in HIV therapy--an exemplifying case].
    Stoehr A
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():70-1. PubMed ID: 15373056
    [No Abstract]   [Full Text] [Related]  

  • 39. Successful desensitization of enfuvirtide-induced skin hypersensitivity reaction.
    Shahar E; Moar C; Pollack S
    AIDS; 2005 Mar; 19(4):451-2. PubMed ID: 15750403
    [No Abstract]   [Full Text] [Related]  

  • 40. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.
    Lalezari JP; Bellos NC; Sathasivam K; Richmond GJ; Cohen CJ; Myers RA; Henry DH; Raskino C; Melby T; Murchison H; Zhang Y; Spence R; Greenberg ML; Demasi RA; Miralles GD;
    J Infect Dis; 2005 Apr; 191(7):1155-63. PubMed ID: 15747252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.